# ENDRA Life Sciences Inc.: financial statements, quarterly

NDRA · Nasdaq · CIK 1681682 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ndra.md) · [Financials](/companies/ndra/financials.md) · [Filings](/companies/ndra/filings.md) · [Insiders](/companies/ndra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ndra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,633](/filings/0001654954-24-014771.md) | [579 d](/filings/0001654954-25-003937.md) | [1,042](/filings/0001654954-25-005770.md) | [716](/filings/0001654954-25-009643.md) | [794](/filings/0001213900-25-110887.md) | [638 d](/filings/0001213900-26-037617.md) | [529](/filings/0001213900-26-057680.md) | [381](/filings/0001213900-26-090027.md) | [432](/filings/0001213900-25-110887.md) | [508 d](/filings/0001213900-26-037617.md) | [776](/filings/0001213900-26-057680.md) | [234](/filings/0001213900-26-090027.md) |
| Operating income | $k | [(3,129)](/filings/0001654954-24-014771.md) | [(1,458) d](/filings/0001654954-25-003937.md) | [(2,781)](/filings/0001654954-25-005770.md) | [(2,231)](/filings/0001654954-25-009643.md) | [(1,509)](/filings/0001213900-25-110887.md) | [(4,297) d](/filings/0001213900-26-037617.md) | [(1,469)](/filings/0001213900-26-057680.md) | [(1,301)](/filings/0001213900-26-090027.md) | [(1,371)](/filings/0001213900-25-110887.md) | [(1,622) d](/filings/0001213900-26-037617.md) | [(2,174)](/filings/0001213900-26-057680.md) | [(1,483)](/filings/0001213900-26-090027.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001654954-24-014771.md) | [0.0 d](/filings/0001654954-25-003937.md) | [0.0](/filings/0001654954-25-005770.md) | [0.0](/filings/0001654954-25-009643.md) | [0.0](/filings/0001654954-24-014771.md) | [0.0 d](/filings/0001654954-25-003937.md) | [0.0](/filings/0001654954-25-005770.md) | [0.0](/filings/0001654954-25-009643.md) | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,101)](/filings/0001654954-24-014771.md) | [(1,460) d](/filings/0001654954-25-003937.md) | [(2,776)](/filings/0001654954-25-005770.md) | [(2,229)](/filings/0001654954-25-009643.md) | [(2,354)](/filings/0001213900-25-110887.md) | [(4,149) d](/filings/0001213900-26-037617.md) | [(1,036)](/filings/0001213900-26-057680.md) | [(1,226)](/filings/0001213900-26-090027.md) | [(1,596)](/filings/0001213900-25-110887.md) | [(3,169) d](/filings/0001213900-26-037617.md) | [(1,311)](/filings/0001213900-26-057680.md) | [160](/filings/0001213900-26-090027.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | [(9.54)](/filings/0001213900-25-110887.md) | not reported | [(1.86)](/filings/0001213900-26-057680.md) | [(1.71)](/filings/0001213900-26-090027.md) | [(2.10)](/filings/0001213900-25-110887.md) | not reported | [(1.09)](/filings/0001213900-26-057680.md) | [0.06](/filings/0001213900-26-090027.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | [(9.54)](/filings/0001213900-25-110887.md) | not reported | [(1.86)](/filings/0001213900-26-057680.md) | [(1.71)](/filings/0001213900-26-090027.md) | [(2.10)](/filings/0001213900-25-110887.md) | not reported | [(1.09)](/filings/0001213900-26-057680.md) | [0.12](/filings/0001213900-26-090027.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | [3.2](/filings/0001213900-26-037617.md) | not reported | [1.8](/filings/0001213900-26-090027.md) | [0.8](/filings/0001213900-25-110887.md) | [0.8](/filings/0001213900-26-090027.md) | [0.4](/filings/0001213900-26-057680.md) | [1.7](/filings/0001213900-26-090027.md) |
| Current assets | $m | [6.4](/filings/0001654954-23-014357.md) | [3.0](/filings/0001654954-25-003937.md) | [1.3](/filings/0001654954-24-006243.md) | [6.7](/filings/0001654954-24-010642.md) | [5.0](/filings/0001654954-24-014771.md) | [3.4](/filings/0001213900-26-037617.md) | [2.2](/filings/0001654954-25-005770.md) | [1.9](/filings/0001654954-25-009643.md) | [1.0](/filings/0001213900-25-110887.md) | [1.0](/filings/0001213900-26-090027.md) | [0.5](/filings/0001213900-26-057680.md) | [5.6](/filings/0001213900-26-090027.md) |
| Total assets | $m | [7.6](/filings/0001654954-23-014357.md) | [6.8](/filings/0001654954-25-003937.md) | [5.1](/filings/0001654954-24-006243.md) | [10.4](/filings/0001654954-24-010642.md) | [8.4](/filings/0001654954-24-014771.md) | [4.5](/filings/0001213900-26-037617.md) | [3.2](/filings/0001654954-25-005770.md) | [2.8](/filings/0001654954-25-009643.md) | [2.0](/filings/0001213900-25-110887.md) | [3.9](/filings/0001213900-26-090027.md) | [3.4](/filings/0001213900-26-057680.md) | [7.9](/filings/0001213900-26-090027.md) |
| Current liabilities | $m | [2.2](/filings/0001654954-23-014357.md) | [0.9](/filings/0001654954-25-003937.md) | [1.2](/filings/0001654954-24-006243.md) | [1.4](/filings/0001654954-24-010642.md) | [0.8](/filings/0001654954-24-014771.md) | [0.6](/filings/0001213900-26-037617.md) | [0.6](/filings/0001654954-25-005770.md) | [0.6](/filings/0001654954-25-009643.md) | [0.8](/filings/0001213900-25-110887.md) | [0.8](/filings/0001213900-26-090027.md) | [0.8](/filings/0001213900-26-057680.md) | [0.8](/filings/0001213900-26-090027.md) |
| Total liabilities | $m | [2.4](/filings/0001654954-23-014357.md) | [1.1](/filings/0001654954-25-003937.md) | [1.4](/filings/0001654954-24-006243.md) | [1.4](/filings/0001654954-24-010642.md) | [1.8](/filings/0001654954-24-014771.md) | [1.9](/filings/0001213900-26-037617.md) | [1.4](/filings/0001654954-25-005770.md) | [1.3](/filings/0001654954-25-009643.md) | [1.8](/filings/0001213900-25-110887.md) | [1.6](/filings/0001213900-26-090027.md) | [1.7](/filings/0001213900-26-057680.md) | [1.6](/filings/0001213900-26-090027.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001654954-25-003937.md) | [0.0](/filings/0001654954-24-006243.md) | not reported | not reported | [0.0](/filings/0001654954-25-003937.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [0.0](/filings/0001654954-23-014357.md) | [0.0](/filings/0001654954-25-003937.md) | [0.0](/filings/0001654954-24-006243.md) | [0.0](/filings/0001654954-24-010642.md) | [0.0](/filings/0001654954-24-014771.md) | [0.0](/filings/0001654954-25-003937.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [5.2](/filings/0001654954-24-014771.md) | [5.7](/filings/0001213900-26-037617.md) | [3.7](/filings/0001654954-25-009643.md) | [9.0](/filings/0001213900-25-110887.md) | [6.6](/filings/0001213900-25-110887.md) | [2.6](/filings/0001213900-26-090027.md) | [1.8](/filings/0001213900-26-090027.md) | [1.5](/filings/0001213900-26-090027.md) | [0.2](/filings/0001213900-25-110887.md) | [2.3](/filings/0001213900-26-090027.md) | [1.8](/filings/0001213900-26-090027.md) | [6.3](/filings/0001213900-26-090027.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,599) d](/filings/0001654954-24-014771.md) | [(2,175) d](/filings/0001654954-25-003937.md) | [(2,144)](/filings/0001654954-25-005770.md) | [(2,083) d](/filings/0001654954-25-009643.md) | [(1,657) d](/filings/0001213900-25-110887.md) | [(1,516) d](/filings/0001213900-26-037617.md) | [(1,293)](/filings/0001213900-26-057680.md) | [(1,114) d](/filings/0001213900-26-090027.md) | [(1,164) d](/filings/0001213900-25-110887.md) | [(1,612) d](/filings/0001213900-26-037617.md) | [(1,120)](/filings/0001213900-26-057680.md) | [(928) d](/filings/0001213900-26-090027.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001654954-24-014771.md) | [6.9 d](/filings/0001654954-25-003937.md) | [27.0](/filings/0001654954-25-005770.md) | [(11.0) d](/filings/0001654954-25-009643.md) | [0.0 d](/filings/0001213900-25-110887.md) | [0.0 d](/filings/0001213900-26-037617.md) | [17.3](/filings/0001213900-26-057680.md) | [0.0 d](/filings/0001213900-26-090027.md) | [0.0 d](/filings/0001213900-25-110887.md) | [0.0 d](/filings/0001213900-26-037617.md) | not reported | not reported |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [247](/filings/0001213900-25-110887.md) | [558](/filings/0001213900-26-057680.md) | [717](/filings/0001213900-26-090027.md) | [761](/filings/0001213900-25-110887.md) | [1,200](/filings/0001213900-26-057680.md) | [2,475](/filings/0001213900-26-090027.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,499,838 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090027.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.